KCPG
CLB icon

Kavar Capital Partners Group’s Core Laboratories CLB Stock Holding History

Kavar Capital Partners Group’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-100
Closed -$19K – 179
2014
Q1 		$19K Buy
+100
New +$18.9K 0.02% 260

Other funds holding CLB

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
VAM
Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WI
WHV Investments San Francisco, California $187M AUM 14.29% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Kavar Capital Partners Group's CLB Position: Q2 2014 in Review

Kavar Capital Partners Group sold out of Core Laboratories (CLB) in Q2 2014, closing a stake of 100 shares — an estimated $19K sold.

Kavar Capital Partners Group first reported a position in CLB in Q1 2014 and held it in 1 quarter. The position peaked at $19K in Q1 2014. 346 funds tracked by Wall St. Rank hold CLB as of Q2 2014.

  • Kavar Capital Partners Group reported no remaining Core Laboratories position as of Q2 2014 after selling out during the quarter.
  • Kavar Capital Partners Group sold 100 Core Laboratories shares in Q2 2014, an estimated $19K.
  • Kavar Capital Partners Group first reported a position in Core Laboratories in Q1 2014 and held it in 1 quarter.
  • Kavar Capital Partners Group's Core Laboratories position peaked at $19K in Q1 2014.
  • 346 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2014.

Based on Kavar Capital Partners Group's 13F filing for Q2 2014, filed 25 Jan 2019.